Recent Updates
Recently added Catalysts

APD916

Phase 1

Narcolepsy With or Without Cataplexy | Small molecule | Other |Pfizer, Inc.|Last Updated: Nov 1, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment72
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01093508Single-dose Safety Study of APD916 in Healthy VolunteersPHASE1 COMPLETED 72Mar 1, 2010Jul 1, 2010Nov 1, 2010 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
APD916DRUG -
Unlock Study Design Details